Capstone Therapeutics Corp. — Form 10-Q Summary
Reporting period: Three and six months ended June 30, 2017; filed August 14, 2017. The supplied metadata identifies Capstone Holding Corp., while the filing identifies the registrant as Capstone Therapeutics Corp. Financial statements are unaudited.
Business Context
The company is a biotechnology business with a single operating segment focused on developing novel peptides. Its principal current program is AEM-28-14, an analog of the Apo E mimetic peptide AEM-28, being developed through 64%-owned LipimetiX Development, Inc. The company operates primarily through a virtual operating model and has no revenue-producing operations following the 2003 sale of its Bone Device Business.
Key Financial Metrics
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| General and administrative expense | $102,000 in 2017 vs. $157,000 in 2016 | $215,000 vs. $382,000 |
| Research and development expense | $112,000 vs. $220,000 | $379,000 vs. $377,000 |
| Total operating expenses | $214,000 vs. $377,000 | $594,000 vs. $759,000 |
| Net loss | $206,000 vs. $390,000 | $593,000 vs. $769,000 |
| Loss per basic and diluted share | $0.01 in both periods | $0.01 in 2017 vs. $0.02 in 2016 |
| Cash flow from operations | Not separately presented | $(261,000) vs. $(319,000) |
- No revenue or operating margin was reported; the company remains in a development-stage operating profile.
- Cash and cash equivalents were $437,000 at June 30, 2017, down from $698,000 at December 31, 2016. Approximately $286,000 was held by the joint venture.
- Total assets were $758,000, including $274,000 of net patent license rights.
- Current liabilities were $1.473 million, including $1.0 million of convertible promissory notes. Stockholders’ equity was negative $715,000.
- The company had $1.6 million of outstanding advances to the joint venture under a revolving loan agreement.
Material Changes Versus Prior Comparable Period
- Second-quarter G&A expense decreased 35%, and research and development expense decreased 49%, primarily because of cost reductions and limited development activity.
- Six-month G&A expense decreased 44%, while six-month R&D expense was essentially unchanged.
- Six-month net loss improved by $176,000, or approximately 23%, compared with the prior-year period.
- Operating cash use improved by $58,000, but cash still declined by $261,000 during the first six months.
Guidance, Outlook, Risks, and Unusual Items
- Management states that additional capital is required to continue operations and materially advance AEM-28-14. Development activities will remain limited unless funding is obtained.
- The company and its joint venture were exploring fundraising, partnering, licensing, strategic transactions, and debt or equity offerings.
- Management disclosed substantial uncertainty regarding the company’s ability to continue as a going concern. Additional funding will be needed for clinical development, research, manufacturing, and regulatory activities.
- After quarter-end, on July 14, 2017, the company raised $3.440 million from BP Peptides, LLC: $1.1025 million from issuing 13.5 million common shares and $2.4275 million from a secured loan due October 15, 2020. Net proceeds were approximately $2.078 million after transaction costs and repayment of $1.079 million of convertible notes and accrued interest.
- The secured loan bears interest at 6% and is secured by all company assets. BP Peptides subsequently held approximately 34.1% of the company’s common stock.
- In August 2017, the company used $1.0 million to purchase 93,458 shares of LipimetiX Series B-2 preferred stock, increasing its as-converted ownership in the joint venture to approximately 62.2%.
- The company disclosed noncompliance with requirements to obtain independent public-accountant audits of its 2015 and 2016 annual financial statements and reviews of certain 2016 and 2017 quarterly reports. It could not predict potential SEC or OTCQB consequences, including possible effects on trading.
- Key risks include inability to obtain funding, clinical or preclinical failure, regulatory delays or failure, competition, intellectual-property impairment, unfavorable financing terms, dependence on the joint venture, and possible loss of OTCQB listing.
- No material legal proceedings were reported. Management stated that no material loss contingency was reasonably possible at the reporting date.
Investor Verification Checklist
- Verify the registrant identity and reconcile the supplied company name with the filing’s identification of Capstone Therapeutics Corp.
- Review the July 2017 financing, including dilution from 13.5 million new shares, loan security terms, interest payments, and repayment obligations.
- Assess post-quarter-end liquidity after repayment of the convertible notes and the $1.0 million investment in LipimetiX.
- Evaluate the going-concern disclosure and the amount and timing of additional funding required for AEM-28-14.
- Confirm the status of SEC reporting compliance and continued OTCQB eligibility.
- Assess the clinical, regulatory, intellectual-property, and funding risks surrounding AEM-28-14 and the LipimetiX joint venture.